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Abstract: The investigation of the constituents that were isolated from Turnera diffusa (damiana) for
their inhibitory activities against recombinant human monoamine oxidases (MAO-A and MAO-B)
in vitro identified acacetin 7-methyl ether as a potent selective inhibitor of MAO-B (IC50 = 198 nM).
Acacetin 7-methyl ether (also known as 5-hydroxy-4′, 7-dimethoxyflavone) is a naturally occurring
flavone that is present in many plants and vegetables. Acacetin 7-methyl ether was four-fold
less potent as an inhibitor of MAO-B when compared to acacetin (IC50 = 50 nM). However,
acacetin 7-methyl ether was >500-fold selective against MAO-B over MAO-A as compared to only
two-fold selectivity shown by acacetin. Even though the IC50 for inhibition of MAO-B by acacetin
7-methyl ether was ~four-fold higher than that of the standard drug deprenyl (i.e., SelegilineTM
or ZelaparTM, a selective MAO-B inhibitor), acacetin 7-methyl ether’s selectivity for MAO-B over
MAO-A inhibition was greater than that of deprenyl (>500- vs. 450-fold). The binding of acacetin
7-methyl ether to MAO-B was reversible and time-independent, as revealed by enzyme-inhibitor
complex equilibrium dialysis assays. The investigation on the enzyme inhibition-kinetics analysis
with varying concentrations of acacetin 7-methyl ether and the substrate (kynuramine) suggested a
competitive mechanism of inhibition of MAO-B by acacetin 7-methyl ether with Ki value of 45 nM.
The docking scores and binding-free energies of acacetin 7-methyl ether to the X-ray crystal structures
of MAO-A and MAO-B confirmed the selectivity of binding of this molecule to MAO-B over MAO-A.
In addition, molecular dynamics results also revealed that acacetin 7-methyl ether formed a stable
and strong complex with MAO-B. The selective inhibition of MAO-B suggests further investigations
on acacetin 7-methyl as a potential new drug lead for the treatment of neurodegenerative disorders,
including Parkinson’s disease.
Keywords: acacetin 7-methyl ether; acacetin; monoamine oxidase-A; monoamine oxidase-B;
molecular docking; molecular dynamics; neurological disorder; Turnera diffusa
1. Introduction
The monoamine oxidases (EC.1.4.3.4; MAO-A and MAO-B) are FAD (flavin adenine
dinucleotide)-dependent enzymes that are responsible for the metabolism of neurotransmitters,
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such as dopamine, serotonin, adrenaline, and noradrenaline, and for the oxidative deamination
of exogenous arylalkyl amines [1,2]. Due to their central role in neurotransmitter metabolism, these
enzymes represent attractive drug targets in the pharmacological therapy of neurodegenerative
diseases and neurological disorders [3,4]. Recent efforts toward the development of MAO inhibitors
have focused on selective MAO-A or MAO-B inhibitors. Selective MAO-A inhibitors are effective in
the treatment of depression and anxiety [5], whereas the MAO-B inhibitors are useful for treatment
Parkinson’s disease and in combination for treatment of Alzheimer’s Disease [4,6–9]. In recent studies,
acacetin was reported as a potent inhibitor of MAO-A and MAO-B isolated from Calea urticifolia [10].
Similarly, acacetin and its derivative, acacetin 7-O-(6-O-malonylglucoside), from Agatache rugosa was
also reported as a selective potent MAO-B reversible inhibitor [11].
Turnera diffusa Willd. ex Schult (known as damiana), which is a native plant to America
and Africa, is traditionally used for the treatment of various diseases, including sexual impotence,
neurasthenia, diabetes mellitus, urine retention, malaria, diarrhea, and peptic ulcer [12]. The plant
is particularly used as a stimulant, an aphrodisiac, and generally as a tonic in neurasthenia and
impotency with long tradition in Central America [13]. Phytochemical studies have revealed flavonoids,
cyanogenic glycosides, terpenoids, and other secondary metabolites as prominent constituents in
Turnera diffusa [14,15]. Several flavonoids from plant sources have been identified as inhibitors of
MAO-A and MAO-B [16]. Based on the fact that damiana contains many flavonoids and that it
is traditionally used as a tonic herb, we postulated that some components of the plant might be
associated with the inhibition of MAOs. In the present study, the constituents that were isolated
from damiana were evaluated for their inhibitory activities against recombinant human MAO-A and
MAO-B. Acacetin 7-methyl ether showed the most potent selective inhibition of the MAO-B enzyme.
The studies were further extended to investigate the selective binding and mode of interaction of
acacetin 7-methyl ether with human MAO-B.
2. Results
2.1. Determination of MAO-A and -B Inhibition Activity
A series of flavonoids and flavonoid glycosides, namely acacetin, acacetin 7-methyl ether, vetulin
(Figure 1), apigenin-7-O-β-D-(6-O-pcoumaroyl) glucoside, echinaticin, tetraphyllin B, tricin-7-glucoside,
diffusavone, turneradiffusin, rhamnosylorientin, rhamnosylvitexin, and turneradin were isolated from
T. diffusa [12].
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at higher concentrations. Even though the potency of inhibition of human MAO-B by acacetin 7-
methyl ether was about four-fold lower when compared to the standard drug deprenyl (a selective 
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Figure 1. Chemical structure of acacetin, acacetin 7-methyl ether and vetulin.
Besides acacetin, acacetin 7-methyl ether and vetulin also showed selective concentration-
dependent inhibition of MAO-B (Table 1, Figure 2). The MAO inhibitory properties of acacetin
have been recently reported [10]. Acacetin 7-methyl ether was >500-fold selective for MAO-B
(IC50 = 0.198 µM) as compared to MAO-A (IC50 = >100 µM) (Table 1). The concentration-dependent
inhibition of MAO-B with acacetin 7-methyl ether showed a plateau at ~80% inhibition (~20% activity
remaining). This may potentially be due to the low solubility of acacetin 7-methyl ether in assay
buffer medium at higher concentrations. Even though the potency of inhibition of human MAO-B by
acacetin 7-methyl ether was about four-fold lower when compared to the standard drug deprenyl (a
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selective MAO-B inhibitor), its selectivity for MAO-B was higher (>500 fold) as compared to deprenyl
(450 fold). Deprenyl (available with the trade name selegiline) is a clinically used drug for the treatment
of Parkinson’s disease and major depressive disorder [17]. Other constituents that were isolated from
T. diffusa only showed moderate inhibition of MAO-A and MAO-B (IC50 in the range of 13–61 µM),
with no significant selectivity towards MAO-B or MAO-A (Table 1). The studies were extended to
investigate the kinetics of inhibition of MAO-B by acacetin 7-methyl ether. Further, characteristics of
the interaction and the putative binding mode of acacetin 7-methyl ether were also investigated using
computational docking of the ligand to the X-ray crystal structures of MAO-A and MAO-B.
Table 1. Inhibition of recombinant human Monoamine Amine Oxidase-A and -B by constituents from
T. diffusa.
Compound MAO-A IC50 (µM) * MAO-B IC50 (µM) * SI MAO-A/-B
Acacetin 7-methyl ether >100.00 0.198 ± 0.001 >505.051
Vetulin 18.799 ± 0.291 0.447 ± 0.010 42.056
Apigenin-7-O-β-D-(6-O-p-coumaroyl) glucoside 22.508 ± 4.440 22.001 ± 1.759 1.023
Echinaticin 21.830 ± 4.367 13.404 ± 0.148 1.703
Tetraphyllin B - - -
Tricin-7-glucoside 50.901 ± 0.506 27.444 ± 0.819 1.854
Diffusavone 19.091 ± 1.450 14.518 ± 0.214 1.314
Turneradiffusin 61.427 ± 3.568 37.250 ± 2.933 1.649
Rhamnosylorientin 34.909 ± 3.887 25.541 ± 2.020 1.366
Rhamnosylvitexin 40.940 ± 6.810 26.286 ± 0.277 1.557
Turneradin 19.169 ± 0.802 13.027 ± 2.142 1.471
Acacetin 0.115 ± 0.004 0.050 ± 0.0025 2.30
Clorgyline 0.0052 ± 0.0001 2.30 ± 0.0570 -
Deprenyl 23.00 ± 1.00 0.051 ± 0.002 450.980
Safinamide # (ref) 90.00 ± 2.470 0.060 ± 0.005 1500.00
* The IC50 values, computed from the dose response inhibition curves, are mean ± S.D. of at least triplicate
observations. SI—Selectivity Index-IC50 MAO-A/IC50 MAO-B inhibition. # Safinamide data from ref. [18].
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of the substrate and fixed concentrations of the inhibitor. The Ki (i.e., inhibition/binding affinity) 
values were computed with double reciprocal Lineweaver–Burk plots. The binding of acacetin 7-
methyl ether to human MAO-B affected the Km value (i.e., the affinity of the substrate for the enzyme) 
without much effects on the Vmax (maximum enzyme activity), indicating that the inhibition of MAO-
B by acacetin 7-methyl ether was competitive (Figure 3). Acacetin 7-methyl ether inhibited the 
enzymatic activity of MAO-B with considerably high affinity (Ki = 45 nM) (Table 2). 
Figure 2. Conce tr ti t inhibition of recombinant human MAO-B by (A) d prenyl,
(B) acacetin, and (C) acacetin 7-methyl ether. Each point shows mean ± SD of three observations.
2.2. Enzyme Kinetics and Mechanism Studies
Acacetin 7-methyl ether was tested against MAO-B at varying concentrations of kynuramine,
which is a nonselective substrate, to investigate the nature of inhibition of the enzyme. Based on
dose-response inhibition, five concentrations of acacetin 7-methyl ether were selected, two below the
IC50 value (100 and 150 nM), one around the IC50 value (200 nM), and two above the IC value (300 n
and 500 nM) for the inhibition kinetics experiments. The assays were run at varying concentrations of
the substrate and fixed concentrations of the inhibitor. The Ki (i.e., inhibition/binding affinity) values
were computed with double reciprocal Lineweaver–Burk plots. The binding of acacetin 7-methyl ether
to human MAO-B affected the Km value (i.e., the affinity of the substrate for the enzyme) without
much effects on th Vmax (maximu enzy e activity), indicating that the inhibition of MAO-B by
acacetin 7-methyl ether was competitive (Figure 3). Acacetin 7-methyl ether inhibited the enzymatic
activity of MAO-B with considerably high affinity (Ki = 45 nM) (Table 2).
Molecules 2019, 24, 810 4 of 15
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Table 2. Inhibition/binding affinity constants (Ki) for inhibition of recombinant human MAO-A and
MAO-B by acacetin, acacetin 7-methyl ether, and deprenyl.
Compounds Monoamine Oxidase-B
Ki (nM) * Type of Inhibition
Acacetin 7-methyl ether 45.0 ± 3.0 Competitive/Partially Reversible
Acacetin 36 ± 4.0 Competitive/Reversible
Deprenyl 29 ± 6.3 Mixed/Irreversible
* Values are ean ± S.D. of triplicate experiments.
2.3. Analysis of Reversibility of Binding of Inhibitor
The characteristics of binding of acacetin 7-methyl ether to MAO-B were also investigated using
an equilibrium-dialysis assay. The inhibitor acacetin 7-methyl ether was incubated at1.0 and 2.0 µM)
with the MAO-B enzyme for 20 min and the resulting enzyme-inhibitor complex preparation was
dialyzed overnight in phosphate buffer. The activity of the enzyme was analyzed before and after the
dialysis (Figure 4). The incubation of MAO-B with 1.0 and 2.0 µM of acacetin 7-methyl ether caused
>60% inhibition of activity and only ~80% activity of the enzyme was recovered after equilibrium
dialysis. Thus, the binding of acacetin 7-methyl ether to MAO-B was partially reversible. The binding
of selective MAO-B inhibitor deprenyl was confirmed to be irreversible (Figure 4).
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was expressed as % of activity. Each point s ows the mean ± S.D. value of three obs rvations.
2.4. Time-Dependent Assay for Enzyme Inhibition
The time depen f binding of acetin 7-methyl ether to MAO-B was analyzed.
The recombinant enzyme was incubated for different times wi th est compounds, namely, deprenyl,
(0.1 0 µM), acacetin 7-methyl eth r (0.50 µM), and cacetin (0.100 µM) (Figure 5). The control without
inhibit rs was also run simultaneously. The activity of the enzym was determined, as d scribed
above, and the percentage of enzyme activity re aining was plotted against the pre-incubation time to
determine the time-dependence of inhibition. The binding/inhibition of MAO-B by acacetin 7-methyl
ether was not dependent on the pre-incubation time (Figure 5).
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2.5. Computa ional Docking Study of Acacetin 7-
Selective interactions of acacetin 7- t re investigated by molecular docking to
understand its binding pose to hMAO-A an h - . r e-di ensional (3D) protein-ligand
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interactions of acacetin (Figure 6A,C, magenta, stick model) and acacetin 7-methyl ether (Figure 6B,D,
cyan, stick model), respectively, with the X-ray crystal structures of MAO-A and MAO-B are presented
in Figure 6. The docking scores and binding free-energies of acacetin 7-methyl-ether and acacetin at
the active sites of the hMAO-A and hMAO-B X-ray crystal structures are shown in Table 3 and their
corresponding putative binding poses are shown in Figure 6. The docking protocol was validated
by self-docking, in which the native ligands, harmine, and pioglitazone, from the X-ray structures
were docked into their corresponding protein’s structures of MAO-A and MAO-B, respectively.
The calculated RMSD between the docked and experimental poses were <0.6 Å, which verified
that the docking protocol was appropriate for this use.
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and acacetin 7-methyl ether (C cyan, stick model) with the X-ray crystal structures of MAO-A and
MAO-B. (A) Acacetin with MAO-A, (B) acacetin 7-methyl ether with MAO-A, (C) acacetin with MAO-B,
and (D) acacetin 7-methyl ether with MAO-B. FAD (C green, stick model), some crystallographic waters
(O red, H gray, stick model), and the important residues of MAO-A and MAO-B (C gray) are also
shown. The black dashed lines represent H-bonding.
Table 3. Glide docking scores and binding free energies of acacetin and acacetin 7-methyl ether to
MAO-A and MAO-B.





MAO-A MAO-B MAO-A MAO-B MAO-A MAO-B
Acacetin 0.115 0.049 −10.685 −11.890 −56.303 −67.205
Acacetin 7-methyl ether >100 0.198 −9.085 −10.708 −31.791 −67.494
* Values are mean ± S.D. of triplicate experiments.
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According to the docking and binding free-energy results, acacetin 7-methyl ether showed better
binding affinity (Docking score = −10.708 kcal/mol, ∆G = −67.494 kcal/mol) to hMAO-B than
hMAO-A (Docking score = −9.085 kcal/mol, ∆G = −31.791 kcal/mol). The experimental data also
supported this (Table 3). The docking results revealed that the binding orientation of acacetin 7-methyl
ether and acacetin were similar to the orientations of the native ligands of the X-ray crystal structures
of MAO-A (PDB ID: 2Z5X) and MAO-B (PDB ID: 4A79). The computational docking studies provided
further insights into selective interactions of acacetin-7-methyl ether with the human MAO-B over
MAO-A. Acacetin 7-methyl ether tightly binds to MAO-B by forming π-π stacking and H-bonding
(at its C4 carbonyl) with Tyr326 and strong hydrophobic interactions with nearby amino acid residues.
Ile199 and Ile316, which are known as critical residues for MAO-B selectivity [19], showed strong
hydrophobic interaction with the acacetin 7-methyl ether. The additional methoxy moiety at the C7
position of acacetin 7-methyl ether compared to acacetin participated in the hydrophobic interactions
with the Ile198. However, for MAO-A, this additional methoxy moiety exhibited bad contact with
Phe352 and Lys305 and this may be the reason for the poorer binding with MAO-A and the selectivity
of acacetin-7-methyl ether for MAO-B over MAO-A. Additionally, the conserved water molecules
within the enzyme active site were important for enhancing the interaction of acacetin-7-methyl ether
with MAO-B. Water-mediated hydrogen bonding was found between acacetin-7-methyl ether and
Tyr188, Tyr435, and Gln65, which was similar to what was found for acacetin binding with MAO-B
(Figure 6C). We also observed water-mediated H-bonding with the carbonyl of Cys172 and the oxygen
at the C7 position of acacetin and acacetin-7-methyl ether (the interaction is not shown in Figure 6).
A previous study on the interaction of acacetin with Cys172 reported direct (not water-mediated)
interaction with Cys172 [11]. Interestingly, in the docked pose of acacetin with MAO-B that was
reported in that study, the chromene moiety was flipped, with its carbonyl pointed towards Cys172.
By contrast, in the docked pose that was determined in the present study, the carbonyl was pointed
away from Cys172. To help determine which docked pose is more likely correct, we studied the
available structures in the Protein Data Bank and found the X-ray crystal structure of MAO-B with
co-crystalized ligand dimethylphenyl-chromone-carboxamide (PDB ID: 6FVZ) to be helpful. In 6FVZ,
two alternate rotamers of Cys172 (side chain dihedral angle chi1 = −158◦ or −86◦), each with an
average occupancy of 50%, were included in the reported structure. The different values for the side
chain dihedral angle of Cys172 open up the possibility of a direct H-bond interaction between Cys172
and acacetin or acacetin-7-methyl ether. The docked pose of acacetin that was reported in this study
adopted a similar orientation for its chromene moiety (with the chromene oxygen being located close
to Cys172) to that of the chromene moiety of the co-crystallized ligand of 6FVZ. These properties
support the reliability of the docked pose that is presented here.
2.6. Molecular Dynamics Study of Acacetin 7-Methyl Ether and MAO-B
Docking alone cannot provide full insight into the binding mode and dynamics of acacetin
7-methyl ether within hMAO-B. Therefore, we carried out a 10 ns MD simulation of the complex of
acacetin 7-methyl ether with MAO-B using Desmond software [20]. The MD simulation suggests
that acacetin-7-methyl ether fits tightly into the binding pocket of MAO-B, since there was very
little deviation in the ligand Root Mean Square Deviation (RMSD) (Figure 7) during the simulation.
No significant flexibility (as measured by Root Mean Square (RMS) fluctuation, RMSF) was observed
in the secondary structure elements (SSE) (α-helices and β-strand: Helix = 28.63%, Strand = 15.78%,
and Total SSE = 44.40%) of the protein model, with major fluctuations only in residues 490–520 and the
loop regions (Figure 8). The %SSE remained close to 45% throughout the simulation. The amino acids
that interacted with acacetin-7-methyl ether did not show any major fluctuations in their RMSF values
(Figure 8). The interaction histograms (Figure 9A) and protein-ligand contact graphs (Figure 9B) were
analyzed to study the time-dependent changes in the interaction of the ligands with key residues of the
protein. The interaction histogram shows that crucial amino acids for interaction with acacetin-7-methyl
ether are Leu171 (hydrophobic and water bridges), Cys172 (hydrogen bond, hydrophobic, and water
Molecules 2019, 24, 810 8 of 15
bridges), Tyr188 (hydrophobic and water bridges), Ile199 (hydrophobic), Gln206 (hydrogen bond and
water bridges), Tyr326 (hydrophobic and water bridges), Tyr398 (water bridges), and Tyr435 (hydrogen
bond, hydrophobic, and water bridges) (Figure 9A). The stabilization of the complex can be mainly
attributed to several H-bond contacts and π-π interactions. H-bond contacts were observed between
oxygen at the C7 position of acacetin-7-methyl ether and Cys172 and between the C5 OH and Tyr435.
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Strong π-π interactions were observed between Tyr326 and Ring B and Ring C of acacetin
7-methyl ether. In addition, the protein-ligan interaction diagram (Figure 9B) indicates that acacetin
7-methyl ether forms H-bond interactions with Cys172 (70% contribution), Gln206 (24% contribution),
and Tyr435 (30% cont ibution), and water-mediated ydrogen bond interact ons with Leu171 (32%
contribution) throughout the 1 ns MD simulatio s. The contribu ion of π-π i teractions wi h Tyr326
was found to be 72% (with Ring C) and 24% (with Ring B). In conclusion, the i teractio histograms and
contact graphs show that acac tin 7-me yl ether forms a significantly stable c mplex with MAO-B.
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are da ag d during the progression of Parkinson’s disea e. Treatment with l vodopa provides
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therapy results in a slowing of the breakdown of levodopa and dopamine in the brain, and it
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selegiline (L-deprenyl), rasagiline, and safinamide. Selegiline and rasagiline are irreversible inhibitors
of MAO and they may be associated with significant side effects [26,27]. Both acacetin, reported
earlier, [10] and acacetin 7-methyl ether reported here show the potent inhibition of MAO-B. However,
acacetin 7-methyl ether showed >500-fold selectivity, compared to only two-fold selectivity of acacetin
for MAO-B over MAO-A. The 7-methyl substitution marginally reduces the potency of MAO-B
inhibition, relative to acacetin (IC50 198 nM vs. 50 nM, respectively), but it dramatically improves
the selectivity (>500) for MAO-B. This suggests a significant scope for further optimization of the
5, 7-dihydroxy-4′-methoxyflavone pharmacophore to achieve high potency and selectivity against
the human MAO-B. 5, 7-Dihydroxy-4′-methoxyflavones represent a new class of selective reversible
MAO-B inhibitors with potential therapeutic application for treatment of neurodegenerative disorders,
including Parkinson’s disease in combination with standard drugs [28]. A recent study has also
reported MAO-A and MAO-B inhibition activity by acacetin 7-O-(6-O-malonylglucoside), a derivative
of acacetin that was isolated from Agastache rugosa plant leaves [11]. The reversibility of MAO-B
inhibition with acacetin 7-methyl ether adds significant value to its potential therapeutic use. A recent
pharmacokinetics study of acacetin metabolism in vitro and in vivo that analysed its metabolites
showed that acacetin is metabolized by the sulfotransferase 1A1 enzyme into acacetin-7-sulfate, which
was detected in vivo in plasma samples and also in vitro from incubation of the Liver S9 fraction [29].
Further, computational analysis of the binding of acacetin 7-methyl ether to human MAO-A and
MAO-B confirmed its selective and stronger interaction with MAO-B when compared to MAO-A. Both
acacetin and acacetin 7-methyl ether interact with Gln65, Cys172, Tyr188, and Tyr435 in human MAO-B.
However, less prominent interactions of acacetin 7-methyl ether with Tyr197 and Tyr407 in MAO-A
as compared to acacetin afforded the higher inhibition of MAO-A with acacetin (IC50 = 0.115 µM)
than with acacetin 7-methyl ether (IC50 = >100 µM). To shed light on the interaction profile, binding
mechanism, and dynamic properties of acacetin 7-methyl ether with MAO-B, we carried out a 10 ns
MD simulation of their protein-ligand complex. The structural and dynamical properties of acacetin
7-methyl ether were analyzed using RMSD plots of the ligand and of the Cα atoms of the protein
(Figure 7), and by RMSF (Figure 8) plots of protein that was bound to the ligand. The RMSD plot of
atom locations vs. simulation time indicated that the protein and ligand maintained a significantly
stable state throughout the simulation (Figure 7). The most significant deviation in RMSD was a result
of the flexible motion of the modeled C-terminal residues (residues 498–520) (not included in Figure 7).
The MD simulations revealed that Leu171, Cys172, Tyr188, Ile199, Gln206, Tyr326, Tyr398, and Tyr435
are crucial amino acids for the interaction of acacetin 7-methyl ether and MAO-B. These results show
us that acacetin 7-methyl ether forms a stable and strong complex with MAO-B.
These studies support the further in vivo evaluation of acacetin, when considering the MAO
inhibitory activities that were reported earlier [10] and those of acacetin 7-methyl ether reported herein,
in experimental animal models for neurological and neurodegenerative diseases.
4. Materials and Methods
4.1. Enzymes and Chemicals
Recombinant human monoamine oxidase-A and monoamine oxidase-B enzymes were obtained
from the BD Biosciences (Bedford, MA, USA). Kynuramine, clorgyline, deprenyl, acacetin, and DMSO
were purchased from Millipore Sigma (St. Louis, MO, USA). Safinamide was purchased from TCI
Chemicals, Portland, OR, USA.
Acacetin 7-methyl ether (purity >98%), vetulin (>97%), apigenin-7-O-β-D-(6-O-pcoumaroyl)
glucoside (>97%), echinaticin (>96%), tetraphyllin B (>98%), tricin-7-glucoside (>98%), diffusavone
(>97%), turneradiffusin (>96%), rhamnosylorientin (>97%), rhamnosylvitexin (>95%), turneradin
(>95%), and acacetin (>96%) were isolated from T. diffusa at the National Center for Natural Products
Research (NCNPR), University of Mississippi, University, MS, USA. Their identities and purities
were confirmed by chromatographic (TLC, HPLC) and spectroscopic (IR, one-dimensional (1D)- and
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two-dimensional (2D)-NMR, HR-ESI-MS) methods, as well as by comparison with the published
spectroscopic data [14,15].
4.2. MAOs Inhibition Assay
To investigate the effect of the isolated constituents from T. diffusa on recombinant human
MAO-A and MAO-B, the kynuramine oxidative deamination assay was performed in 384-well
plates, as previously reported, with minor modifications [30,31]. A single fixed concentration of
kynuramine substrate and varying concentrations of inhibitor were used to test enzyme inhibition
and determine the IC50 values. Kynuramine concentrations for MAO-A and MAO-B were 80 µM
and 50 µM, respectively. These concentrations of kynuramine were twice the apparent KM value for
substrate binding [10,31]. The concentrations that were tested for pure constituents were from 0.01
to 100 µM, for MAO-A and MAO-B inhibition assays. Reactions were performed in a clear 384-well
microplate (50 µL) with 0.1 M potassium phosphate buffer, pH 7.4. The inhibitors and compounds
were dissolved in DMSO, diluted in the buffer solution, and pre-incubated at 37 ◦C for 10 min (no more
than 1.0% DMSO final concentration). The reactions were initiated by the addition of 12.50 µL MAO-A
(to 5 µg/mL) or MAO-B (to 12.5 µg/mL), incubated for 20 min at 37 ◦C, and then terminated by the
addition of 18.8 µL of 2N NaOH. The enzyme product 4-hydroxyquinoline formation was recorded
fluorometrically using a SpectraMax M5 fluorescence plate reader (Molecular Devices, Sunnyvale,
CA, USA) with an excitation (320 nm) and emission (380 nm) wavelength, using the SoftMaxPro 6.0
program. The inhibition effects of enzyme activity were calculated as a percent of product formation
when compared to the corresponding control (enzyme-substrate reaction) without inhibitors. Controls,
including samples in which the enzyme or the substrate was added after stopping the reactions, were
simultaneously checked to determine the interference of inherent fluorescence of the test compounds
with the measurements. IC50 values for MAO-A and MAO-B inhibition were calculated from the
concentration dependent inhibition curves using XLfit, a Microsoft Excel-based plug-in which performs
Regression, curve fitting and statistical analysis (IDBS, Bridgewater, NJ, USA).
4.3. Determination of IC50 Values
To determine the IC50 values for the inhibition of MAO-A and MAO-B by acacetin 7-methyl ether,
the enzyme assay was performed at a fixed concentration of the substrate kynuramine for MAO-A
(80 µM) and for MAO-B (50 mM) and with varying concentrations of inhibitor/test compounds for
MAO-A and MAO-B (0.01 µM to 100 µM). The dose-response curves were generated using Microsoft®
Excel and the IC50 values were analyzed using XLfit software.
4.4. Enzyme Kinetics and Mechanism Studies
For the determination of the binding affinity of the inhibitor (Ki) with MAO-A and MAO-B,
the enzyme assays were carried out at different concentrations of kynuramine substrate (1.90 µM
to 500 µM) and varying concentrations of the inhibitors/compound. Compounds acacetin and
acacetin 7-methyl ether were tested at 0.030–0.100 µM and 0.100–0.500 µM, respectively, for MAO-B
to determine the Km and Vmax values of the enzymes in the presence of the inhibitor. The controls
without inhibitor were also simultaneously run. The results were analyzed by standard double
reciprocal Line–Weaver Burk plots for computing Km and Vmax values, which were further analyzed
to determine Ki values [10].
4.5. Analysis of Reversibility of Binding of Inhibitor
The inhibitors bind with the target enzyme through the formation of an enzyme-inhibitor complex.
The formation of the enzyme-inhibitor complex may be accelerated in the presence of the high
concentration of the inhibitor. The reversibility of binding of MAO inhibitory compound acacetin
7-methyl ether was determined by the formation of the complex by incubating the enzyme with a
high concentration of the inhibitor, followed by extensive dialysis of the enzyme-inhibitor complex
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and the recovery of catalytic activity of the enzymes. The MAO-B (0.2 mg/mL protein) enzyme
was incubated with each inhibitor: acacetin (0.5 µM), acacetin 7-methyl ether (1.0, 2.0 µM), deprenyl
(0.5 µM), and safinamide (0.2 µM) in a total volume of 1 mL, 100 mM potassium phosphate buffer
(pH 7.4). After 20 min incubation at 37 ◦C, the reaction was stopped by chilling in an ice bath. All of
the samples were dialyzed against potassium phosphate buffer (25 mM; pH 7.4) at 4 ◦C for 14–18 h
(three buffer changes). Control enzyme (without inhibitor) was also run through the same procedure
and the activity of the enzyme was determined before and after the dialysis [18].
4.6. Time-Dependent Assay for Enzyme Inhibition
To analyze whether the binding of the inhibitor with MAO-B was time-dependent, the enzyme
was pre-incubated for different time periods (0–15 min) with the inhibitors at a concentration that
produces approximately 70–80% inhibition. The inhibitor concentrations used to test time-dependent
inhibition were acacetin (0.1 µM), acacetin 7-methyl ether (0.5 µM), and deprenyl (0.1 µM) with MAO-B
(12.5 µg/mL). The controls without inhibitors were also simultaneously run. The activities of the
enzymes were determined, as described above, and the percentage of enzyme activity remaining was
plotted against the pre-incubation time to determine the time-dependence of inhibition.
4.7. Computational Methods
The X-ray crystal structures of MAO-A (PDB accession number: 2Z5X [32]) and MAO-B
(PDB accession number: 4A79 [33]) were downloaded from the Protein Data Bank website. These
proteins were prepared by adding hydrogens, adjusting bond orders and proper ionization states,
and refining overlapping atoms. The water molecules beyond 5 Å from the co-crystalized ligands
were removed and the ligand states were generated using Epik at pH 7.4. During the refinement
process, the water molecules with less than two H-bonds to non-waters were also removed. Acacetin
and acacetin-7-methyl ether were sketched in Maestro [34], prepared, and energy-minimized at a
physiological pH of 7.4 using the LigPrep [35] module of the Schrödinger software (Cambridge, MA,
USA) [36]. Acacetin was used as a positive control for the docking studies. For protein and ligand
preparation, we used the Optimized Potentials for Liquid Simulations 3 (OPLS3) force field. The active
sites of the MAO-A and MAO-B proteins were each defined by the centroid of the co-crystallized
ligands that were present in 2Z5X and 4A79, respectively. We did not remove cofactor FAD during
protein preparation and docking. Acacetin and acacetin 7-methyl ether were docked using the Induced
Fit docking [37] protocol, applying the standard-precision (SP) docking method. The top 10 poses were
kept for analysis. The best docking poses were subjected to binding free-energy calculations using the
Prime MM-GBSA module of Schrödinger software.
4.8. Molecular Dynamics (MD) Simulations
Monoamine oxidase B consists of a two-domain molecular architecture. Each identical monomer
consists of 520 amino acids. In this study, we used one monomer (chain A) for the docking and MD
simulations. It is reported [38] that the C-terminal helix (residues 498–520) of MAO-B is located in the
outer membrane of mitochondria. The MAO-B X-ray crystal structure that we used (PDB ID: 4A79)
contains only 501 residues; therefore, we modeled its missing residues that were known to be embedded
in lipid bilayer using the Maestro molecular modeling suite [39]. The Protein Preparation Wizard [40]
of Maestro was used to prepare the protein structure. We used the Desmond [20] Molecular Dynamics
System, ver. 3.6 (Schrödinger) with the OPLS-3 force field and RESPA [41] integrator to perform a 10 ns
MD simulation. The best scoring pose of acacetin-7-methyl ether in complex with MAO-B (PDB ID:
4A79) was selected and the C-terminal residues of the protein-ligand complex between amino acids
498 and 520 were embedded into a pre-equilibrated 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(POPC) membrane and the rest of the system was solvated with TIP3P [42] explicit waters. The whole
system was neutralized using sodium chloride (NaCl) and it was set to an ionic strength of 0.15 M.
The buffer dimensions of the orthorhombic simulation box were set to 30 × 30 × 70 Å3. The solvated
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system was energy-minimized with the DESMOND minimization algorithm for 2000 iterations when
considering a convergence threshold of 1.0 kcal/mol/Å. The constructed system was simulated with
the relaxation protocol in Desmond [20]. The protocol involved an initial minimization of the solvent,
while keeping restraints on the solute, followed by short MD simulations, including the following steps:
(1) Simulation (100 ps) using Brownian dynamics, in the NVT ensemble at 10 K with solute heavy atoms
restrained; (2) Simulation (12 ps) in the NVT ensemble using a Berendsen thermostat (10 K) with solute
heavy atoms restrained; (3) Simulation (12 ps) in the NPT ensemble using a Berendsen thermostat
(10 K) and a Berendsen barostat (1 atm) with non-hydrogen solute atoms restrained; (4) Simulation
(12 ps) in the NPT ensemble using a Berendsen thermostat (300 K) and a Berendsen barostat (1 atm)
with non-hydrogen solute atoms restrained; and, (5) Simulation (24 ps) in the NPT ensemble using a
Berendsen thermostat (300 K) and a Berendsen barostat (1 atm) with no restraints. The production run
was carried out using an NPT ensemble at 300 K with Nosé–Hoover temperature coupling [43] and
at a constant pressure of 1.01 bar via Martyna–Tobias–Klein pressure coupling [44]. The simulation
trajectories (frames) were sampled at intervals of 4.8 ps. We used a timestep of 2.0 fs. The resulting
trajectory was analysed using the Simulation Interactions Diagram (SID) utility of Desmond [20].
Finally, the PyMOL 1.4.1 and Maestro 11.5.011 molecular graphics systems were used to visualize the
protein-ligand complex and to generate all of the figures.
5. Conclusions
Biological screening of constituents of Turnera diffusa (damiana) identified three O-methyl flavones,
namely, acacetin, acacetin 7-methyl ether, and vetulin as selective inhibitors of human MAO-B. Acacetin
7-methyl ether was a highly potent and selective MAO-B inhibitor with >500-fold selectivity towards
MAO-B when compared to MAO-A. Further studies suggested that acacetin 7-methyl ether is a
reversible competitive inhibitor of MAO-B. Computational docking analysis confirmed the selective
binding of acacetin 7-methyl ether to human MAO-B as compared to MAO-A. Acacetin 7-methyl
ether may have a potential therapeutic application for the treatment of neurodegenerative disorders,
including Parkinson’s disease.
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